A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: Pharmacokinetics, safety, and efficacy

Journal of Acquired Immune Deficiency Syndromes

Volumn 26, Issue 3, 2001, Pages 218-224

  Burger, David M ^a   Hugen, Patricia W H ^a   Aarnoutse, Rob E ^a   Dieleman, Jeanne P ^b   Prins, Jan M ^c   Van Der Poll, Tom ^c   Ten Veen, Jacob H ^d   Mulder, Jan W ^e   Meenhorst, Pieter L ^e   Blok, Willem L ^f   Van Der Meer, Jan T M ^c   Reiss, Peter ^c,g   Lange, Joep M A ^c,g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

^f Ziekenhuis Walcheren   (Netherlands)

^g Natl AIDS Therapy Evaluation Centre   (Netherlands)

Author keywords

Efficacy; Indinavir; Pharmacokinetics; Ritonavir; Safety

Indexed keywords

INDINAVIR; RITONAVIR;

ADVERSE DRUG REACTION; AREA UNDER THE CURVE; CHEMOTHERAPY INDUCED EMESIS; COHORT ANALYSIS; COMPARTMENT MODEL; DATA BASE; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; VIRUS LOAD;

EID: 0035280509     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200103010-00003     Document Type: Review

References (25)

1. Treatment with indinavir, zidovudine and lamivudine: Three year follow-up
2. Treatment of HIV infection. Tolerability of commonly used antiretroviral agents
3. Longer-term immunologic effects and side effects of successful antiretroviral therapy
4. Clinically relevant drug interactions with antiretroviral agents
5. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients
6. Indinavir (IDV) pharmacokinetics are related to efficacy and toxicity
7. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy
8. A pilot study of nevirapine, indinavir and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
9. A 24-week open-label phase I/II evaluation of the HIV-protease inhibitor MK-39 (indinavir)
10. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir
11. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers
12. Multiple-dose pharmacokinetics and tolerability of indinavir-ritonavir combinations in healthy volunteers
13. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography
14. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography
15. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring
16. Combination therapy with indinavir and ritonavir in antiretroviral-experienced patients
17. Adherence communication: A qualitative analysis of physician-patient dialogue
18. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children
19. BID first-line ritonavir/indinavir 400/400 MG plus double nucleoside combination therapy
20. The steady-state pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
21. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease-inhibitor cross-resistance: A survey of over 6000 samples
22. Combining ritonavir (RTV) & indinavir (IDV) decreases IDV-associated urinary & renal adverse events (AES)
23. Nephropathy and renal colic in patients treated with indinavir, ritonavir + indinavir or ritonavir + saquinavir
24. Lipid profiles in patients on ritonavir/indinavir-containing salvage regimens
25. Virologic & immunologic response to combination protease inhibitor (PI) therapy with ritonavir (RTV) & indinavir (IDV) in antiretroviral naive HIV+ patients